Organ Doses Research Articles

Real-time dose prediction for Artemis missions

As large solar energetic particle (SEP) events can add significant radiation dose to astronauts in a short period of time and even induce acute clinical responses during missions, they present a concern for manned space flight operation. To assist the operations team in modeling and monitoring organ doses and any possible acute radiation-induced risks to astronauts during SEP events in real time, ARRT (Acute Radiation Risks Tool) 1.0 has been developed and successfully tested for Artemis I mission. The ARRT 2.0 described in this work integrates an established SEP forecasting model – UMASEP-100, further enabling real-time dose prediction for the upcoming Artemis II and following missions. With the new module linking with UMASEP-100 outputs in real time, the total BFO doses of most significant events can be communicated at the time of onset and hours before the peak. This is based on a flux-dose formula identified from comparing UMASEP-100 results with transport calculation for the events during 1994-2013 and validated with events outside that period. ARRT 2.0 also shows capability to distinguish minor events from significant ones to screen false alarms that will cause disruptions for space activities. This improvement provides additional information for operational teams to make timely decisions in contingent scenarios of severe SEP events to mitigate radiation exposure.

Estimation of Organ Dose, Effective Dose, and Cancer Risk in Abdominal CT Scan Patients

Computed tomography scan (CT scan) is a modality that is used to diagnose diseases inside the human body. In the scanning process, the patient will receive radiation from the CT scanner, so that it is necessary to calculate the amount of radiation dose. The purpose of this study was to determine the organ dose, effective dose, and cancer risk received by abdominal examination patients. Data taken from the results of abdominal examination patients at Radiology Installation of A.W. Sjahranie Regional Hospital Samarinda using 16-slice CT scan modality GE BRIVO type D3161T. The data collected included 150 patients, both female and male, with ages ranging from 15 to 79 years. Dosimetry parameters taken from CT scan results are the exposure factor (kV, mAs), scan length, computed tomography dosimetry indeks volume (CTDIvol), and dose length product (DLP) of the patient. CTDIvol and DLP of the patient are used to calculate the organ dose, effective dose, and cancer risk values of abdominal CT scan patients. Then the effective dose value received by the abdominal CT scan examination patient is compared with the Nuclear Energy Regulatory Agency of Indonesia (BAPETEN) standard based on the CTDIvol and DLP values of the patient, and also compared with the International Commission Radiological Protection (ICRP) standard. Based on the results of organ dose estimation calculations, the average value of the stomach is 0.82 mSv, the gonads are 0.54 mSv, and the bladder is 0.28 mSv. Meanwhile, the average value of effective dose received by abdominal examination patients is 5.28 mSv with an average cancer risk of 0.029 %. Based on the CTDIvol and DLP values of the patients, the 3rd quartile values of the patients were 8.25 mGy and 413.84 mGy.cm. This value is still below the value recommended by BAPETEN when viewed from the 2021 Diagnostic Reference Level (DRL) guidelines. The effective dose received by one patient exceeded the standard set by the ICRP. Meanwhile, the cancer risk received by patients is still in a low percentage.

Estimation and analysis of S values for 131I using paediatric mesh type reference computational phantoms

This study examines the effect of paediatric mesh-type reference computational phantoms on organSvalues resulting from radioiodine (131I) intake. Using Geant4, we estimated131ISvalues for 30 radiosensitive target tissues due to emission from the thyroid (Target ← Thyroid) in these phantoms. Our results show thatSvalues differ between male and female phantoms of the same age andSvalues also decrease as phantom age increases. The male-to-femaleSvalue ratio typically varies within 10%, with larger differences observed for the esophagus, extra-thoracic regions, muscles, bladder, and sex organs. On average,Svalues for mesh phantoms are approximately 17% higher than those for voxel phantoms, with larger discrepancies for organs remodelled separately in mesh phantoms. The study provides organSvalues for the paediatric population due to131I exposure from the thyroid, based on the reference mesh-type computational phantoms, enhancing organ dose estimation in emergency situations and during radioiodine treatment.

Dosimetric and biological impact of activity extravasation of radiopharmaceuticals in PET imaging.

The increasing use of nuclear medicine and PET imaging has intensified scrutiny of radiotracer extravasation. To our knowledge, this topic is understudied but holds great potential for enhancing our understanding of extravasation in clinical PET imaging. This work aims to (1) quantify the absorbed doses from radiotracer extravasation in PET imaging, both locally at the site of extravasation and with the extravasation location as a source of exposure to bodily organs and (2) assess the biological ramifications within the injection site at the cellular level. A radiation dosimetry simulation was performed using a whole-body 4D Extended Cardiac-Torso (XCAT) phantom embedded in the GATE Monte Carlo platform. A 10-mCi dose of 18F-FDG was chosen to simulate a typical clinical PET scan scenario, with 10% of the activity extravasated in the antecubital fossa of the right arm of the phantom. The extravasation volume was modeled as a 5.5mL rectangle in the hypodermal layer of skin. Absorbed dose contributions were calculated for the first two half-lives, assuming biological clearance thereafter. Dose calculations were performed as absorbed doses at the organ and skin levels. Energy deposition was simulated both at the local extravasation site and in multiple organs of interest and converted to absorbed doses based on their respective masses. Each simulation was repeated ten times to estimate Monte Carlo uncertainties. Biological impacts on cells within the extravasated volume were evaluated by randomizing cells and exposing them to a uniform radiation source of 18F and 68Ga. Particle types, their energies, and direction cosines were recorded in phase space files using a separate Geant4 simulation to characterize their entry into the nucleus of the cellular volume. Subsequently, the phase space files were imported into the TOPAS-nBio simulation to assess the extent of DNA damage, including double-strand breaks (DSBs) and single-strand breaks (SSBs). Organ-level dosimetric estimations are presented for 18F and 68Ga radionuclides in various organs of interest. With 10% extravasation, the hypodermal layer of the skin received the highest absorbed dose of 1.32±0.01Gy for 18F and 0.99±0.01Gy for 68Ga. The epidermal and dermal layers received absorbed doses of 0.07±0.01Gy and 0.13±0.01Gy for 18F, and 0.14±0.01Gy and 0.29±0.01Gy for 68Ga, respectively. In the extravasated volume, 18F caused an average absorbed dose per nucleus of 0.17±0.01Gy, estimated to result in 10.58±0.50 DSBs and 268.11±12.43 SSBs per nucleus. For 68Ga, the absorbed dose per nucleus was 0.11±0.01Gy, leading to an estimated 6.49±0.34 DSBs and 161.24±8.12 SSBs per nucleus. Absorbed doses in other organs were on the order of micro-gray (µGy). The likelihood of epidermal erythema resulting from extravasation during PET imaging is low, as the simulated absorbed doses to the epidermis remain below the thresholds that trigger such effects. Moreover, the organ-level absorbed doses were found to be clinically insignificant across various simulated organs. The minimal DNA damage at the extravasation site suggests that long-term harm, such as radiation-induced carcinogenesis, is highly unlikely.

Monte Carlo study of organ doses and related secondary cancer risk estimations for patients undergoing prostate radiotherapy: Algerian population-based study

The present study aimed to assess organ doses and the associated cancer risks related to secondary radiation (photons and neutrons) exposure during 3D Conformational Radiotherapy (3D-CRT) for patients with prostate cancer in Algeria. To this purpose, a detailed geometric Monte Carlo (MC) modeling of the LINAC, combined with a hybrid whole-body phantom was carried out. The secondary radiation doses were calculated in patient's organs, both within and outside the field. The obtained doses were used to estimate the Lifetime Attributable Risks (LARs) for cancer incidence for out of field organs, using the Biological Effects of Ionizing Radiation VII (BEIR VII) risk model, considering the exposure age range according to the age of the treated patients in Algeria. The survival information and baseline cancer risks were based on relevant statistics for the Algerian population. The results revealed that secondary radiation equivalent doses mostly depend on the distance of organs from the treated volume. The highest and lowest equivalent doses of 5.77 mSv/Gy and 0.24 mSv/Gy were recorded in the small intestine and ocular lens, respectively. LARs decreased as the age of exposure increased, with the highest estimated value per 100,000 individuals identified at a 35-year exposure age (88 for the colon and 15 for the intestine). Conversely, the lowest risks were found at 70 years of age, specifically in rib bone and leg bone with value of (0). The current research could contribute to establishing a database concerning the incidence of secondary cancers induced by radiotherapy during 3D-CRT for prostate cancer in Algeria.

Evaluating Factors Affecting Mean Glandular Dose in Mammography: Insights from a Retrospective Study in Dubai.

This study evaluates the mean glandular dose (MGD) in mammography screening for women aged 40-69 in Dubai, based on a retrospective analysis of a dose survey involving 2599 participants. MGD was calculated using the Dance formula. The average MGD was 0.96 ± 0.39 mGy for mediolateral oblique (MLO) views and 0.81 ± 0.33 mGy for craniocaudal (CC) views. Weak inverse correlations were found between age and organ dose (OD) for both views, while a direct relationship was observed between breast thickness and entrance skin dose (ESD). In adjusted models, ESD was strongly associated with MGD (β = 1.04, 95% CI: 0.97, 1.09), while OD showed a moderate association (β = 0.44, 95% CI: 0.40, 0.49). Significant variations in ESD, OD, and MGD were noted across age groups and breast thicknesses. Lower MGD indicates reduced radiation exposure risk, while higher MGD in MLO views suggests improved imaging quality. Monitoring and optimizing MGD are essential for enhancing patient safety and screening efficacy.

Monte Carlo Simulation of Organ Absorbed Dose of Worker's Radiation Exposure in Bone Scintigraphy

Objectives: This study examines individual organ doses and the impact of ionizing radiation sources on effective radiation doses. Methods: In the research, the ICRP-defined adult standing phantom was used as the phantom material in the Visual Monte Carlo Dose Calculation Program (VMC). Subsequently, the incurred doses were calculated by defining different doses, distances, and durations for the 99mTc radioactive source. Results: Exposure times were set at 5 minutes and 20 minutes in comparison. The results indicated that for 5 minutes and 20 minutes at 360 cm, doses remained below the ICRP recommended annual dose limit of 5.7 µSv/h for occupational exposure. Conclusion: Organ absorbed and effective doses varied with exposure time and source-phantom distance. To optimize radiation exposure, people working in radiation fields must make an increased effort to reduce radiation doses following the ALARA principles. Keywords: Effective dose, absorbed dose, VMC software, Monte Carlo

Simulation of the shielding effect of lead apron undergoing chest CT scan.

Lead aprons are used to reduce radiation dose to patients. As the distance between the lead apron and the edge of the scan range increases, organ dose is expected to decrease, but with increasing scattered radiation dose in the body. By simulation, this work aims at estimate whether the organ dose increases due to the scattered radiation in the body with lead apron. A standard-sized male and a female phantom is used to simulate organ doses of chest scans in various lead apron shielding situations. Simulations in this work considered different distance between the edge of the 0.35-mm lead apron and the edge of the scan range. For the female phantom, the dose to the gonads was significantly reduced (56% on average), but not as much as men (78% on average). However, the amount of dose reduction is small for male and female phantoms (0.0082mGy/100mAs and 0.0160mGy/100mAs).

Attempt to re-estimate organ doses of victims in non-homogeneous exposure accident by means of the state-of-the-art Mesh-type Reference Computational Phantom-a case study of an IR-192 source accident.

An attempt was made to estimate organ doses of a victim in a high-dose non-homogeneous exposure accident caused by a sealed 192Ir gamma-ray source. The Gilan accident was selected as a case study. Organ doses including testis, red bone marrow and so on were properly estimated by applying the Monte Carlo calculation with the state-of-the-art adult male Mesh type Reference Computational Phantom. By introducing a complicated exposure scenario, the dose distribution on the right chest of the victim in the Gilan accident could be reproduced to a certain extent.

CTNI-63. RHENIUM (186RE) OBISBEMEDA (RHENIUM NANOLIPOSOME,186RNL) FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES (LM): SUMMARY OF THE PHASE 1 DOSE ESCALATION STUDY AND PHASE 2 ADMINISTERED DOSE SELECTION

Abstract BACKGROUND Leptomeningeal metastases (LM) is a devastating systemic cancer complication most often seen with breast, lung, and melanoma, with limited treatment options and poor survival. Rhenium (186Re) Obisbemeda (186RNL) provides the combination of effective therapeutic beta radiation, simultaneous gamma-decay for imaging, and ~90-hour physical half-life for optimal radiation delivery. A summary of the Phase 1 dose escalation study, expected to be completed, will be presented. METHODS ReSPECT-LM is a Phase 1 dose escalation study for patients with LM from any primary cancer. Adult patients are given a single dose of 186RNL via intraventricular catheter (Ommaya reservoir) in an outpatient setting to determine the maximum tolerated/feasible dose (MTD/MFD), safety, and tolerability. Seven administered dose cohorts in a 3 + 3 design, from 6.6 mCi to 109.96 mCi, were anticipated. RESULTS For the first 5 cohorts, doses were well-tolerated; most AEs were Grade 1 and 2 with 1 DLT (Cohort 5) at time of abstract submission. CSF tumor cell enumeration assays were performed with a maximum reduction over baseline seen at Day 28. Radiation absorbed doses were calculated for the ventricles, cranial subarachnoid space, and spinal fluid and showed a linear increase with administered dose, with liver and spleen remaining low. Neurological symptoms were reported to improve. We expect the Phase 1 conclusion and the RP2D to be determined for conference reporting; additionally, based on duration of benefit seen during the Phase 1, a multidose paradigm will be initiated to extend benefit. CONCLUSION A single dose of 186RNL for patients with LM has been well-tolerated, with high absorbed doses to the treatment area, acceptable organ doses, and promising clinical improvement and reductions in tumor cell count. Phase 2 is expected to begin enrollment by Q4 2024. Additionally, based on these data, a Phase 1 multidose study is planned to be initiated this year.

Development of a novel automated algorithm for patient dosimetry in computed tomography: a step towards the facilitation of size-specific dose estimates and organs dosimetry estimations in a busy clinical workflow

Abstract Accurate dosimetry in computed tomography (CT) is essential for patient safety and effective radiation management. This study presents the development of an automated algorithm designed to enhance patient dosimetry by facilitating size-specific dose estimates (SSDE) and organ dose estimations. Utilizing a Python-based script, the proposed method integrates advanced image preprocessing, contour detection, and mathematical calculations to quantify key metrics from CT images. This automated approach addresses the limitations of manual measurement techniques. A retrospective analysis was conducted on CT axial images from examinations acquired with an 80-detector scanner. The algorithm processes DICOM images, converts pixel values to Hounsfield Units, applies Gaussian smoothing, windowing, and thresholding, followed by morphological operations to refine segmentation. It measures the water equivalent diameter (Dw) and estimates both region SSDE and organ doses, incorporating tissue attenuation. Validation was performed using an adult anthropomorphic ATOM phantom, with organ doses measured by optically stimulated luminescence dosimeters. The results demonstrated the algorithm’s potential in estimating SSDE and organ doses. Validation of the automated method revealed strong correlations for Dw and SSDE between the proposed method and manual measurements of five expert reviewers ranging from 0.86 to 0.99 for determination coefficient. Comparative analysis of organ doses showed close agreement between results from experimental setup against the proposed algorithm. The automated algorithm estimated brain dose with a mean of 21.8 mGy, while measurements from the ATOM phantom and CT Expo indicated 19.74 mGy and 23.05 mGy, respectively. For lung doses, the automated algorithm estimated 12.5 mGy compared to 11.0 mGy from the ATOM phantom and 13.1 mGy from CT Expo. Liver doses were measured at 12.7 mGy by the automated method, versus 12.1 mGy from the ATOM phantom and 11.1 mGy from CT Expo. This study shows the potential of automated image analysis techniques in enhancing dosimetry accuracy in CT examinations.

EFFECTIVE DOSE ANALYSIS IN ABDOMEN AP EXAMINATION PATIENTS WITH CALDOSE_X VERSION 5.0

This study evaluates radiation dose exposure during diagnostic radiology procedures using X-rays and their potential risks, including cancer, to optimize radiation safety through the CALDose_X software that calculates the absorbed organ dose, effective dose, and cancer risk, according to the lowest possible achievable (ALARA) principle. This study used a quantitative experimental design to evaluate the impact of filter thickness variations on Entrance Surface Air Kerma (ESAK) and effective dose by analyzing data from 54 patients undergoing AP Abdominal X-ray examinations. The results showed that the effective dose to the abdominal organs varied with exposure factors and Focus to Detector Distance (FDD), where the colon wall had the highest sensitivity with doses ranging from 0.030 mSv to 0.126 mSv, followed by the stomach and pancreas. Increasing kV, mAs, and FDD increased the effective dose, emphasizing the importance of careful dose management. This study concluded that exposure factors and FDD affect the effective dose received by the abdominal organs, with recommendations to monitor patient doses, revise national diagnostic reference levels, and establish standard protocols with health authorities. Keywords: CALDose_X, X-ray Exposure Factor, patient dose, ESAK, Effective Dose, Abdomen AP.

Evaluation of radiation dose and cancer risk for paediatric digital radiography in a Moroccan hospital

Pediatric radiography is the first line of most diagnostic examinations and an effective tool that provides important information about the patient's health status.This study aims to investigate the Entrance Surface Dose (ESD) and organ doses for pediatric patients undergoing imaging procedures of the abdomen, chest, pelvis, and nasopharynx using Optically Stimulated Luminescence Dosimeters OSLDs and an anthropomorphic phantom.An ATOM pediatric 5-year-old phantom was imaged using a Digital Radiography (DR) based on similar conditions of routine radiography (exposure parameters kVp, mAs, SID: Source Image receptor Distance). The OSLDs were inserted at the appropriate sites to measure localized doses in the sensitive organs.The results showed that the entrance surface doses for the pediatric patients were 0.17 ± 0.03 mGy, 0.10 ± 0.00 mGy, 0.46 ± 0.00 mGy, and 0.42 ± 0.02 mGy, respectively, for the abdomen (AP), chest (AP), pelvis (AP), and nasopharynx (LAT). The range of organ doses were 0.05–0.45 mGy, 0.01–0.44 mGy, 0.13–1.05 mGy, and 0.084–0.99 mGy for the abdomen, chest, pelvis, and nasopharynx examination, respectively. Effective doses (ED) were 0.088 ± 0.021 mSv, 0.011 ± 0.004 mSv, 0.058 ± 0.007 mSv, and 0.044 ± 0.024 mSv for the abdomen, chest, pelvis, and nasopharynx examination, respectively.The likelihood of cancer, as determined by the ICRP health risk model with a rate of 500 cases per 10 000 person-Sv (5% per sievert), estimated that a 0.015 case of health risk (0.3 person-Sv × 5% per sievert) may in the future be attributable to four X-ray pediatric procedures conducted in 2022.The ESD, ED, and organ dose values are deemed acceptable compared to those reported in the literature. Although the risk of incidence and mortality from cancer during life is minimal, it should not be ignored.

Influence of X-ray spectrum and bowtie filter characterisation on the accuracy of Monte Carlo simulated organ doses: Validation in a whole-body CT scanning mode

PurposeFor patient-specific CT dosimetry, Monte Carlo dose simulations require an accurate description of the CT scanner. However, quantitative spectral information and information on the bowtie filter material and shape from the manufacturer is often not available. In this study, the influence of different X-ray spectra and bowtie filter characterisation methods on simulated CT organ doses is studied. MethodsUsing ImpactMC, organ doses of whole-body CTs were simulated in twenty adult whole-body voxel models, generated from PET/CT examinations previously conducted in these patients. Simulated CT organ doses based on the manufacturer X-ray spectra and bowtie filter data were compared with those obtained using alternative characterisation models, including spectrum generators and experimentally measured dose data. A total of four different X-ray spectra and one bowtie filter model were defined based on these data. ResultsFor all X-ray spectra and bowtie filter combinations, estimated CT organ doses are within 6% from those resulting from simulations with the CT characterisation models provided by the manufacturer. While varying the bowtie filter model results in CT organ dose differences smaller than 1%, dose differences up to 6% are observed when X-ray spectra are not based on the quantitative data from the manufacturer. ConclusionsEstimated organ doses slightly depend on the applied CT characterisation model. When manufacturer’s data are not available, half-value layer and dose measurements provide sufficient input to obtain equivalent X-ray spectra and bowtie filter profiles, respectively.

Retrospective biodosimetry: Conversion of frequency of chromosomal translocations into organ doses

Introduction. One of the techniques used in retrospective biodosimetry according to the fluorescence in situ hybridization (FISH) method involves the estimation of stable chromosome aberrations (translocations) in human peripheral blood T-lymphocytes. In the case of uniform external and internal exposure, the interpretation of FISH data does not pose any problem, since the dose to T-lymphocytes that effects the translocation frequency can be simply interpreted as the dose to other organs and tissues. However, when the internal exposure is non-uniform and the doses to the organs differ by an order of magnitude, conversion from frequency of translocation to dose estimates becomes a complicated task.Objective. To review the main parameters necessary for the retrospective assessment of doses using the FISH method in the case of internal uneven and prolonged β-irradiation.Findings. The present analytical review considers problems associated with determining the following parameters: (1) Frequency of radiation-induced and background translocations; (2) Conversion factors from the frequency of radiation-induced translocations to the dose to T-lymphocytes (α); (3) Conversion factors from the dose to T-lymphocytes (cytogenetic dose) to the dose to critical organs and tissues (Borg ), which depend on age at the time of exposure. General approaches and estimates of (α) based on the construction of in vivo and in vitro calibration curves for external and internal exposure were analyzed. The dose-accumulation features in different T-cell populations from prolonged internal non-uniform exposure (using 90Sr as an example) were considered in terms of the applicability of the model approach to assessing accumulated doses. Uncertainties of dose estimates in retrospective biodosimetry are discussed and further research directions proposed.Conclusions. In the case of non-uniform internal exposure with a low dose rate, converting translocation frequency to dose estimates becomes a complex task. The α and Borg conversion coefficients, which are derived from independent data sets, can be based on various approaches, including modelling. Currently, approaches to assessing their uncertainties, as well as the uncertainties of the dose obtained using the FISH method, remain undeveloped. Therefore, these coefficients require further studies.

Diagnostic performance of digital tomosynthesis for postoperative assessment of acetabular fractures and pelvic ring injuries.

Digital tomosynthesis (DTS) has broad non-orthopaedic applications and has seen limited use within orthopaedics for imaging of the wrist. The utility of DTS for assessing reduction and hardware placement following operative treatment of pelvic ring injuries and acetabular fractures has not previously been investigated. All operatively treated acetabular fractures and pelvic ring injuries that underwent surgical fixation within a one-year time span received both a computed tomography (CT) scan and a DTS scan as part of their routine postoperative imaging workup. Three orthopaedic traumatologists independently reviewed the images for face-value clinical utility. Radimetrics and PCXMC software were utilized on a subset of the study population's DTS and CT studies to calculate the effective and organ radiation doses delivered. 52 patients (22 acetabular fractures, 22 pelvic ring injuries, 7 pelvic ring and acetabular fractures, 2 femoral head & acetabular fractures) were included. DTS was considered adequate to assess reduction 83% of the time, hardware position 83% of the time, and sufficient to replace the CT scan 67% of the time. DTS was associated with an 8.3 times lower effective radiation dose than CT. All organ doses were lower for DTS than CT. DTS appears to have face-value clinical utility for assessing reduction and hardware position following surgical treatment of acetabular fractures and pelvic ring injuries. Given that DTS is associated with significantly lower radiation doses to patients, further study utilizing more objective criteria is warranted.

Preclinical Aspects of [89Zr]Zr-DFO-Rituximab: A High Potential Agent for Immuno-PET Imaging.

An early diagnosis of cancer can lead to choosing more effective treatment and increase the number of cancer survivors. In this study, the preparation and preclinical aspects of [89Zr]Zr-DFO-Rituximab, a high-potential agent for PET imaging of Non- Hodgkin Lymphoma (NHL), were evaluated. DFO was conjugated to rituximab monoclonal antibody (mAb), and DFO-rituximab was successfully labeled with zirconium-89 (89Zr) at optimized conditions. The stability of the complex was assessed in human blood serum and PBS buffer. Radioimmunoreactivity (RIA) of the radioimmunoconjugate (RIC) was evaluated on CD20-overexpressing Raji cell line and CHO cells. The biodistribution of the radiolabeled mAb was studied in normal and tumorbearing rodents. Finally, the absorbed dose in human organs was estimated. The radiolabeled compound was prepared with radiochemical purity (RCP) >99% (RTLC) and a specific activity of 180±1.8 GBq/g. The RCP of the final complex PBS buffer and human blood serum was higher than 95%, even after 48 h post incubation. The RIA assay demonstrated that more than 63% of the radiolabeled compound (40 ng/ml, 0.5 mL) was bound to 5×106 Raji cells. The biodistribution of the final product in tumor-bearing mice showed a high accumulation of the RIC in the tumor site in all intervals post-injection. Tumor/ non-target ratios were increased over time, and longer imaging time was suggested. The dosimetry data indicated that the liver received the most absorbed dose after the complex injection. [89Zr]Zr-DFO-Rituximab represents a significant advancement in the field of oncological imaging and offers a robust platform for both diagnostic and therapeutic applications in the management of B-cell malignancies.

Construction of new polygon mesh-type phantoms based on adult Japanese voxel phantoms.

To construct adult Japanese phantoms applicable to individual exposure dose assessments, we created adult Japanese polygon mesh-type male (JPM) and female (JPF) phantoms through modification of the adult Japanese voxel phantoms, JM-103 (male) and JF-103 (female). The body sizes and masses of organs, tissues, and organ contents in JPM and JPF were adjusted to the Japanese averages, except for those unimportant for radiation protection or risks. The JPM and JPF data were converted to tetrahedral mesh-type data and incorporated into the Particle and Heavy Ion Transport code System (PHITS) for dose calculations. The dosimetric characteristics of the JPM and JPF phantoms were validated by calculating their effective doses in the anterior-posterior geometry for the external irradiation of photons with energies of 0.01-20 MeV and compared with those of JM-103 and JF-103 or the reference values given in ICRP Publication 116. The results confirmed no problems applying JPM and JPF to dose assessments in adult Japanese subjects. Furthermore, it was found that JPM and JPF can also accurately calculate the absorbed doses for entire organs and high radiosensitive cell regions with thin, small, and complicated structures.

The Australian paediatric brachytherapy experience: A pathway to a national programme.

Paediatric cancers are rare, and most children requiring radiation therapy receive external beam radiation (EBRT). Although EBRT may offer organ preservation compared to surgery, it can be associated with significant late effects. Image-guided brachytherapy is a highly specialised technique offering both organ preservation and dose conformity to minimise late toxicity. This is a retrospective mono-institutional review of paediatric brachytherapy in one of the largest paediatric centres in Australia. Outcomes and toxicities are presented as well as brachytherapy versus proton plan comparison in four patients. A total of 14 patients were treated with adjuvant brachytherapy between 2012 and 2022. The predominant histology was rhabdomyosarcoma, and all patients had pelvic tumours. High-dose rate (HDR) brachytherapy was given for 13 patients with one patient receiving low-dose rate (LDR) brachytherapy. Only one grade three late toxicity was reported and two patients developed metastatic disease within one year of completion of treatment. The brachytherapy plan was superior to protons in two of four patients and equivocal in one patient. This is the first Australian publication of a paediatric brachytherapy series from a single institution. This retrospective series demonstrates the feasibility and safety of brachytherapy in paediatric pelvic tumours. The initial work presented here demonstrates the value of a comprehensive radiation plan review in selecting the optimal modality for an individual paediatric patient.

First-in-human study of dosimetry, safety and efficacy for [177Lu]Lu-P15-073: a novel bisphosphonate-based radioligand therapy (RLT) agent for bone metastases.

Bisphosphonates are pivotal in managing bone tumors by inhibiting bone resorption. This study investigates the therapeutic potential of [177Lu]Lu-P15-073, a novel bisphosphonate, for radioligand therapy (RLT) in bone metastases. Ten patients (age 35 to 75) with confirmed bone metastases underwent therapy with a single dose of [177Lu]Lu-P15-073 (1,225 ± 84 MBq, or 33 ± 2 mCi). Prior to treatment, bone metastases were verified via [99mTc]Tc-MDP bone scans. Serial planar whole-body scans monitored biodistribution over a 14-day period. Dosimetry was assessed for major organs and tumor lesions, while safety was evaluated through blood biomarkers and pain scores. Serial planar whole-body scans demonstrated rapid and substantial accumulation of [177Lu]Lu-P15-073 in bone metastases, with minimal uptake in blood and other organs. The absorbed dose in the critical organ, red marrow, was measured at (0.034 ± 0.010 mSv/MBq), with a notably low normalized effective dose (0.013 ± 0.005 mSv/MBq) compared to other 177Lu-labeled bisphosphonates. Persistent high uptake in bone metastases was observed, resulting in elevated tumor doses (median 3.12Gy/GBq). Patients exhibited favorable tolerance to [177Lu]Lu-P15-073 therapy, with no new instances of side effects. Additionally, 87.5% (7/8) of patients experienced a significant reduction in pain scale (numerical rating scale, NRS, from 5.1 ± 2.3 to 3.0 ± 1.8). The tumor-background ratio (TBRmean) of [99mTc]Tc-MDP correlated significantly with [177Lu]Lu-P15-073 uptake (P < 0.01), indicating its potential for prediction of absorbed dose. This study demonstrates the safety, dosimetry, and efficacy of a single therapeutic dose of [177Lu]Lu-P15-073 in bone metastases. The treatment was well-tolerated with no severe adverse events. These findings suggest that [177Lu]Lu-P15-073 holds promise as a novel RLT agent for bone metastases.